JOURNAL ARTICLE

Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice.

  • Published In: Multiple Sclerosis Journal, 2025, v. 31, n. 3. P. 376 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Inojosa, Hernan; Kather, Annika; Akgün, Katja; Ziemssen, Tjalf 3 of 3

Abstract

The article discusses the challenges and implications of variability in anti-JCV antibody serology assays in natalizumab treatment for multiple sclerosis (MS) patients. The introduction of natalizumab biosimilars has led to inconsistencies in test results, complicating risk management and undermining clinician confidence. Standardization and transparency in JCV testing practices are urgently needed to ensure reliable risk stratification, enhance patient safety, and maintain effective MS treatment protocols. The article emphasizes the importance of monitoring JCV antibody status for managing PML risk in natalizumab-treated MS patients and advocates for greater transparency, independent validation of tests, and centralized testing in accredited laboratories to improve patient safety and treatment outcomes. [Extracted from the article]

Additional Information

  • Source:Multiple Sclerosis Journal. 2025/03, Vol. 31, Issue 3, p376
  • Document Type:Letter
  • Subject Area:Health and Medicine
  • Publication Date:2025
  • ISSN:1352-4585
  • DOI:10.1177/13524585241300972
  • Accession Number:183687382
  • Copyright Statement:Copyright of Multiple Sclerosis Journal is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.